Clinical observation in designated COVID-19 hospitals in China has showed that TCM including the Lianhua Qingwen Capsule are effective in the treatment of over 90 percent of all confirmed COVID-19 cases on the Chinese mainland.
Developed under the guidance of collateral disease theory, the medicine is listed as the recommended medicine for the treatment of cold and influenza by China’s National Health Commission and National Administration of Traditional Chinese Medicine. Composed of 13 Chinese herbs, the TCM has been found in the clinical research that it is effective in alleviating the influenza-induced symptoms like fever, cough and fugue.
There is no evidence so far that the coronavirus can be transmitted by mosquitoes, China's top respiratory expert, Zhong Nanshan, said on Monday during a video conference with staff members from the Confucius Institute and Chinese students studying abroad.
JAKARTA - Penyebaran wabah virus Corona (Covid-19) di dunia masih belum mereda termasuk di Indonesia. Pemasalahannya sampai saat ini belum ada vaksin dan obat khusus untuk menyembuhkan pasien Covid-19.
SHIJIAZHUANG, China, 23 de abril de 2020 /PRNewswire/ -- A Yiling Pharmaceutical (002603.SZ) anunciou que as cápsulas (granulos) da Lianhua Qingwen foram adicionadas ao "Esquema de diagnóstico e tratamento da pneumonia pelo novo coronavírus no Laos" (Vers?o II do Estudo) como o quarto medicamento tradicional chinês para o tratamento da pneumonia por COVID-19 no Laos.
China has donated 100,000 boxes of Lianhua Qingwen — a compound of herbal medicine that has been proved effective for treating COVID-19 patients — to Italy to help treat its patients there, experts said. The traditional Chinese medicine, which is said to kill viruses and remove lung heat, is suitable for clinical treatment of COVID-19 patients with a serious fever and constipation, Zhang Boli, an academician of the Chinese Academy of Engineering and president of Tianjin University of TCM, said on Monday at a news conference held in Wuhan by the State Council Information Office.
SHIJIAZHUANG, China, April 15, 2020 /PRNewswire/ -- On April 14, 2020, Yiling Pharmaceutical announced that Yiling Pharmaceutical and its subsidiary Beijing Yiling Pharmaceutical had received the approval document of drug supplement application concerning the application for new indications of Lianhua Qingwen capsules and Lianhua Qingwen granules issued by State Drug Administration. Lianhua Qingwen capsule and Lianhua Qingwen granules were approved to add "functional indications" to the originally approved indications: "In the conventional treatment of novel coronavirus pneumonia, it can be used for a light, common type of fever, cough, and fatigue", "Usage and dosage" increased "COVID-19 light, normal treatment for 07-22 days" and so on.
On April 4, 2020, Phoenix TV broadcast a report on Yiling Pharmaceutical. It was reported that the global epidemic continued to worsen. At the China-Europe anti-epidemic exchange meeting, the recovery rate of patients treated with Lianhua Qingwen Capsule of Yiling Pharmaceutical co., LTD was as high as 91.5 percent, which has become a hot spot. Since 2004, Lianhua Qingwen Capsule has been listed by the national health commission of China, the state administration of traditional Chinese medicine and other departments in the treatment of influenza and other respiratory diseases for more than 20 times. It has played an important role in the prevention and control of major epidemics. On March 30, Lianhua Qingwen Capsule was approved by the ministry of health of Thailand for the registration of modern herbal medicine, which indicated that Yiling pharmaceutical co., a representative of modern Chinese medicine enterprises in China, had the qualification to sell Lianhua Qingwen Capsule as a drug in the Thai market.